Drug Profile
Mycobacterium ulcerans vaccine - Swiss TPH Institute/Telormedix
Alternative Names: TMX 201 adjuvant-based Buruli ulcer vaccine - Swiss TPH Institute/Telormedix; TMX-201Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Swiss Tropical and Public Health Institute
- Developer Swiss Tropical and Public Health Institute; Telormedix
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Buruli ulcer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Buruli-ulcer (Prevention) in Switzerland (Parenteral)
- 09 Jan 2014 Phase I development is ongoing in Switzerland